Biomarkers of left ventricular hypertrophy and remodeling in blacks

Hypertension

Volumn 58, Issue 5, 2011, Pages 920-925

  Coutinho, Thais ^a   Al Omari, Malik ^b   Mosley Jr , Thomas H ^c   Kullo, Iftikha J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenomedullin; Atrial natriuretic peptide; Biomarkers; Brain natriuretic peptide; Endothelin; Left ventricular hypertrophy; Osteoprotegerin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN; OSTEOPROTEGERIN; PROADRENOMEDULLIN;

ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; FEMALE; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; VENTRICULAR REMODELING;

EID: 83155181505     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.178095     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics: 2011 update-a report from the American Heart Association. Circulation. 2011;123: e18-e209.
2. Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, Mc GTSA. Racial differences in cardiac structure and function in essential hypertension. BMJ. 1994;308:1011-1014. (Pubitemid 24115035)
3. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis. 1988;12:285-290.
4. Solberg LA, McGarry PA. Cerebral atherosclerosis in Negroes and Caucasians. Atherosclerosis. 1972;16:141-154.
5. Havranek EP, Froshaug DB, Emserman CD, Hanratty R, Krantz MJ, Masoudi FA, Dickinson LM, Steiner JF. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med. 2008;121: 870-875.
6. Kardia SL, Rozek LS, Krushkal J, Ferrell RE, Turner ST, Hutchinson R, Brown A, Sing CF, Boerwinkle E. Genome-wide linkage analyses for hypertension genes in two ethnically and geographically diverse populations. Am J Hypertens. 2003;16:154-157. (Pubitemid 36143437)
7. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, II, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83-89. (Pubitemid 46014067)
8. Al-Omari MA, Khaleghi M, Mosley TH Jr, Morgenthaler NG, Struck J, Bergmann A, Kullo IJ. Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension. J Hum Hypertens. 2011;25:106-113.
9. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458. (Pubitemid 16119719)
10. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in nor-motensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
11. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. (Pubitemid 41821197)
12. Kim CX, Bailey KR, Klee GG, Ellington AA, Liu G, Mosley TH Jr, Rehman H, Kullo IJ. Sex and ethnic differences in 47 candidate pro-teomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS One. 2010;5:e9065.
13. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172. (Pubitemid 351193639)
14. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996;28:22-30. (Pubitemid 26231085)
15. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens. 1999;12:921-924. (Pubitemid 29469947)
16. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12: 1508-1515. (Pubitemid 32666334)
17. Rutten JH, van der Velde N, van der Cammen TJ, ten Cate FJ, Vletter WB, Boomsma F, van den Meiracker AH. Associations between plasma natriuretic peptides and echocardiographic abnormalities in geriatric outpatients. Arch Gerontol Geriatr. 2008;47:189-199. (Pubitemid 352010385)
18. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288:1252-1259. (Pubitemid 35001328)
19. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009;157:746-753.e2.
20. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008;118:2252-2258, 5p following 2258.
21. Arnlov J, Lind L, Stridsberg M, Andren B, Lithell H. N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males. J Intern Med. 2000;247:699-708. (Pubitemid 30430347)
22. Sayama H, Nakamura Y, Saito N, Kinoshita M, Suda M. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects. Gerontology. 2000;46:71-77. (Pubitemid 30103517)
23. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens. 2004;22: 1597-1604. (Pubitemid 39037612)
24. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
25. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system: II-natriuretic peptide receptors. J Hypertens. 1992;10:1111-1114.
26. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49:1114-1119. (Pubitemid 351664304)
27. Al-Omari MA, Khaleghi M, Mosley TH Jr, Turner ST, Morgenthaler NG, Struck J, Bergmann A, Kullo IJ. Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension. Am J Hypertens. 2009;22: 860-866.
28. Bhandari SS, Davies JE, Struck J, Ng LL. The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. Metabolism. 2010;59:7-13.
29. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 2005; 25:2480-2487. (Pubitemid 43732267)
30. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498-503. (Pubitemid 30080863)
31. Morimoto A, Nishikimi T, Yoshihara F, Horio T, Nagaya N, Matsuo H, Dohi K, Kangawa K. Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. Hypertension. 1999;33:1146-1152. (Pubitemid 29230964)
32. Zhang JJ, Yoshida H, Chao L, Chao J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive Dahl salt-sensitive rats. Hum Gene Ther. 2000;11: 1817-1827.
33. Hua L, Li C, Xia D, Qu P, Li Z, Zhang W, Feng X. Relationship between hypertensive left ventricular hypertrophy and levels of endothelin and nitric oxide. Hypertens Res. 2000;23:377-380. (Pubitemid 30445001)
34. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE sub study. Losartan Intervention for Endpoint-Reduction in Hypertension. Am Heart J. 2002;144:530-537.
35. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96: 1593-1597. (Pubitemid 27375357)
36. Grainger DJ, Witchell CM, Weissberg PL, Metcalfe JC. Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture. Cardiovasc Res. 1994;28:1238-1242. (Pubitemid 24264732)
37. Noheria A, Mosley TH Jr, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens. 2010; 23:767-774.
38. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci. 2005;108:237-243.
39. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-2180. (Pubitemid 38625393)
40. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail. 2007;9:357-363. (Pubitemid 46441975)